Skip to main content
      RT @Janetbirdope: Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could ta

      Janet Pope Janetbirdope

      4 years 5 months ago
      Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 ⁦@RheumNow⁩ #EULAR2021 ⁦@eular_org⁩ https://t.co/8WCrt11ubV
      Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.
      Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage.

      https://t.co/NzB

      Dr. John Cush RheumNow

      4 years 5 months ago
      Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage. https://t.co/NzB2e2Vfwb
      RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen

      Dr. John Cush RheumNow

      4 years 5 months ago

      RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

      RT @ARD_BMJ: From bedside to bench–unexpected results of clinical studies that changed our understanding of the diseas

      ARD & RMD Open ARD_BMJ

      4 years 5 months ago
      From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY
      RT @KDAO2011: Novel MOA Rx SLE skin #OP0132
      Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of

      k dao KDAO2011

      4 years 5 months ago
      Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq
      RT @Stiddyo: What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed

      Paul Studenic Stiddyo

      4 years 5 months ago

      What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

      RT @KDAO2011: “When patients present with LN, they already lost alot of nephrons!”
      - Prof F Houussiau on th

      k dao KDAO2011

      4 years 5 months ago
      “When patients present with LN, they already lost alot of nephrons!” - Prof F Houussiau on the importance of early aggressive Rx for LN #EULAR2021 @rheumnow
      RT @Janetbirdope: Patient with SLE says I am flaring BUT you say No! Just like in RA, there often is poor QoL. POS0101 D

      Janet Pope Janetbirdope

      4 years 5 months ago
      Patient with SLE says I am flaring BUT you say No! Just like in RA, there often is poor QoL. POS0101 Despite response to Rx SF36 shows less QoL vs pop’n. Need to look at what can be improved beyond active SLE #EULAR ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/C17FRTBsUq
      RT @Janetbirdope: RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it

      Janet Pope Janetbirdope

      4 years 5 months ago
      RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
      RT @ejdein1: OPO132: Dr. Werth presents Iberdomide targeting cereblon ligand on SLE skin. Iberdomide 0.45 mg QD showed i

      Eric Dein ejdein1

      4 years 5 months ago
      OPO132: Dr. Werth presents Iberdomide targeting cereblon ligand on SLE skin. Iberdomide 0.45 mg QD showed improvement vs PBO for SCLE & CCLE, not seen for ACLE. Interesting new target, affects B cell and type 1 IFN pathways @Rheumnow #Eular2021 https://t.co/nuDM7h59MB
      RT @RheumatologyNet: Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of p

      Rheumatology Network RheumatologyNet

      4 years 5 months ago
      Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ
      ×